SetPoint Launches IDE Trial Of Vagus Nerve Stimulation To Treat Arthritis
The randomized trial will evaluate SetPoint's bioelectronic platform in patients with moderate-to-severe rheumatoid arthritis, supported by funds secured in a recent preferred stock financing.
You may also be interested in...
The US Medicare agency issued on 12 January its final MCIT rule allowing instant reimbursement for FDA breakthrough devices – unless the incoming Biden administration blocks it.
Start-Up Spotlight: SetPoint Develops Vagus Nerve Stimulation To Treat Crohn's Disease And Rheumatoid Arthritis
SetPoint Medical is developing vagus nerve stimulation technology for Crohn’s disease and rheumatoid arthritis and believes it will be a "platform technology" for treating a variety of autoimmune diseases.
SetPoint Medical announced the launch of a multicenter clinical trial to test its vagus nerve stimulation system in rheumatoid arthritis patients who did not adequately respond to multiple biologic agents. Among the company's backers are Medtronic, Boston Scientific and GSK.